Utah Medical Products, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US9174881089
USD
55.99
1.11 (2.02%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

18.88 k

Shareholding (Mar 2025)

FII

3.66%

Held by 34 FIIs

DII

58.33%

Held by 39 DIIs

Promoter

0.00%

How big is Utah Medical Products, Inc.?

22-Jun-2025

As of Jun 18, Utah Medical Products, Inc. has a market capitalization of 175.34 million, with net sales of 39.28 million and a net profit of 12.95 million over the latest four quarters.

Market Cap: As of Jun 18, Utah Medical Products, Inc. has a market capitalization of 175.34 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 39.28 million and a net profit of 12.95 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 117.43 million and total assets of 122.54 million.

Read More

What does Utah Medical Products, Inc. do?

22-Jun-2025

Utah Medical Products, Inc. manufactures disposable medical devices for hospitals and is classified as a micro-cap company with a market cap of $175.34 million. As of March 2025, it reported net sales of $10 million and a net profit of $3 million.

Overview:<BR>Utah Medical Products, Inc. is engaged in producing disposable medical devices for hospital use, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 10 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: 3 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 175.34 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 14.00<BR>- Dividend Yield: 188.39%<BR>- Debt Equity: -0.71<BR>- Return on Equity: 11.07%<BR>- Price to Book: 1.50<BR><BR>Contact Details:<BR>- Address: 7043 S Cottonwood St, MIDVALE UT : 84047-1048<BR>- Tel: 1 801 5661200<BR>- Website: http://www.utahmed.com

Read More

Should I buy, sell or hold Utah Medical Products, Inc.?

22-Jun-2025

Who are in the management team of Utah Medical Products, Inc.?

22-Jun-2025

As of March 2022, the management team of Utah Medical Products, Inc. includes Kevin Cornwell (Chairman, President, CEO, Secretary), Ernst Hoyer (Lead Independent Director), Paul Richins (Director), Dr. James Beeson (Independent Director), and Dr. Barbara Payne (Independent Director).

As of March 2022, the management team of Utah Medical Products, Inc. includes Mr. Kevin Cornwell, who serves as the Chairman of the Board, President, Chief Executive Officer, and Secretary. Other members of the management team are Mr. Ernst Hoyer, the Lead Independent Director; Mr. Paul Richins, a Director; Dr. James Beeson, an Independent Director; and Dr. Barbara Payne, also an Independent Director.

Read More

Is Utah Medical Products, Inc. overvalued or undervalued?

20-Sep-2025

As of July 7, 2025, Utah Medical Products, Inc. is considered undervalued with attractive valuation metrics, despite recent stock performance lagging behind the S&P 500, indicating a potential investment opportunity.

As of 7 July 2025, the valuation grade for Utah Medical Products, Inc. has moved from expensive to attractive, indicating a shift in perception regarding its value. The company appears undervalued, supported by a P/E ratio of 14, an EV to EBIT of 7.70, and a Price to Book Value of 1.56. In comparison, its peer CareDx, Inc. has a significantly higher P/E ratio of approximately 27.91, while Tactile Systems Technology, Inc. shows an EV to EBITDA of 9.59, further illustrating Utah Medical's relative valuation appeal.<BR><BR>Despite the attractive valuation, Utah Medical's recent stock performance has lagged behind the S&P 500, with a 1-year return of -5.62% compared to the S&P 500's 17.14%. This underperformance over the longer term, particularly a 3-year return of -26.66% versus the S&P 500's 70.41%, may raise concerns among investors, but the current valuation metrics suggest that the stock could be a compelling opportunity.

Read More

Is Utah Medical Products, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Utah Medical Products, Inc. shows a bullish technical trend with positive momentum indicators across multiple timeframes, having returned 11.01% over the past month, outperforming the S&P 500's 2.33%, despite a 1-year underperformance of -5.62% compared to the S&P's 17.14%.

As of 11 September 2025, the technical trend for Utah Medical Products, Inc. has changed from sideways to bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, indicating positive momentum. Bollinger Bands are bullish for both weekly and monthly periods, reinforcing the bullish stance. Daily moving averages also confirm a bullish trend. The KST is bullish weekly and mildly bullish monthly, while the Dow Theory shows a mildly bullish stance on the monthly timeframe. <BR><BR>In terms of performance, the stock has returned 11.01% over the past month, significantly outperforming the S&P 500's 2.33% return, but it has underperformed over longer periods, such as the 1-year return of -5.62% compared to the S&P 500's 17.14%. Overall, the current technical stance is bullish, with moderate strength indicated by multiple bullish signals across different timeframes.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor long term growth as Operating profit has grown by an annual rate -3.25% of over the last 5 years

 
2

The company has declared Negative results for the last 5 consecutive quarters

3

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 203 Million (Micro Cap)

stock-summary
P/E

14.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

162.65%

stock-summary
Debt Equity

-0.70

stock-summary
Return on Equity

10.68%

stock-summary
Price to Book

1.73

Revenue and Profits:
Net Sales:
10 Million
(Quarterly Results - Jun 2025)
Net Profit:
3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.3%
0%
-8.3%
6 Months
-0.02%
0%
-0.02%
1 Year
-13.06%
0%
-13.06%
2 Years
-34.1%
0%
-34.1%
3 Years
-37.02%
0%
-37.02%
4 Years
-50.21%
0%
-50.21%
5 Years
-36.59%
0%
-36.59%

Utah Medical Products, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-2.47%
EBIT Growth (5y)
-3.25%
EBIT to Interest (avg)
16.41
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.71
Sales to Capital Employed (avg)
0.38
Tax Ratio
18.30%
Dividend Payout Ratio
30.42%
Pledged Shares
0
Institutional Holding
83.92%
ROCE (avg)
42.45%
ROE (avg)
12.53%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
1.56
EV to EBIT
7.70
EV to EBITDA
6.29
EV to Capital Employed
2.94
EV to Sales
2.52
PEG Ratio
NA
Dividend Yield
180.08%
ROCE (Latest)
38.15%
ROE (Latest)
11.07%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 50 Schemes (37.83%)

Foreign Institutions

Held by 34 Foreign Institutions (3.66%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 3.09% vs 5.43% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 3.45% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "10.00",
          "val2": "9.70",
          "chgp": "3.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4.00",
          "val2": "3.90",
          "chgp": "2.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "3.00",
          "val2": "3.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "321.10%",
          "val2": "324.70%",
          "chgp": "-0.36%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -18.53% vs -4.02% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -16.27% vs 0.61% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "40.90",
          "val2": "50.20",
          "chgp": "-18.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "18.60",
          "val2": "24.80",
          "chgp": "-25.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.10",
          "val2": "-1.70",
          "chgp": "-23.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "13.90",
          "val2": "16.60",
          "chgp": "-16.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "384.60%",
          "val2": "367.10%",
          "chgp": "1.75%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
10.00
9.70
3.09%
Operating Profit (PBDIT) excl Other Income
4.00
3.90
2.56%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
3.00
3.00
Operating Profit Margin (Excl OI)
321.10%
324.70%
-0.36%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 3.09% vs 5.43% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 3.45% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
40.90
50.20
-18.53%
Operating Profit (PBDIT) excl Other Income
18.60
24.80
-25.00%
Interest
0.00
0.00
Exceptional Items
-2.10
-1.70
-23.53%
Consolidate Net Profit
13.90
16.60
-16.27%
Operating Profit Margin (Excl OI)
384.60%
367.10%
1.75%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -18.53% vs -4.02% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -16.27% vs 0.61% in Dec 2023

stock-summaryCompany CV
About Utah Medical Products, Inc. stock-summary
stock-summary
Utah Medical Products, Inc.
Pharmaceuticals & Biotechnology
Utah Medical Products, Inc. (UTMD) is engaged in the business of producing medical devices that are disposable and for hospital use. The Company's product categories include labor and delivery/obstetrics, including fetal monitoring accessories, Vacuum-Assisted Delivery Systems (VAD), and other labor and delivery tools; neonatal intensive care, including DISPOSA-HOOD, DELTRAN PLUS and GESCO; gynecology/urology/electrosurgery, including LETZ System, FINESSE+ Generator, EPITOME, PATHFINDER PLUS, HOLMIUM LASER FIBRES, LIBERTY System, ENDOCURETTE, TVUS/HSG-Cath and LUMIN, and blood pressure monitoring, including DELTRAN Disposable Pressure Transducer (DPT), and pressure monitoring accessories, components and other molded parts. UTMD markets a range of medical devices used in critical care areas, especially the neonatal intensive care unit, the labor and delivery department and the women's health center in hospitals, as well as products sold to outpatient clinics and physician's offices.
Company Coordinates stock-summary
Company Details
7043 S Cottonwood St , MIDVALE UT : 84047-1048
stock-summary
Tel: 1 801 5661200
stock-summary
Registrar Details